Alzheimer’s disease (AD) is one of the primary dementia causes worldwide. For this reason, there is a need for plasma-based diagnostic biomarkers to facilitate the timely diagnosis of AD. This work synthesizes the current evidence concerning the tau protein p-tau phosphorylated at threonine 217 (p-tau217) as an emerging biomarker, emphasizing its utility in preclinical phases and its potential application in Latin American populations. The findings indicate that p-tau217 has superior sensitivity and specificity compared to classical biomarkers such as p-tau181 and Aβ42. Likewise, its plasma concentration regulates neuropathological progression, as studies by Braak have shown, enabling it to identify alterations from the early stages. In Latin America, studies in Peru, Colombia, and Brazil have shown promising results, albeit with methodological limitations. Some of them have small sample sizes or lack neuroimaging confirmation. Additionally, clinical factors common in the region, such as hypertension, diabetes, or chronic kidney disease, may alter the clinical interpretation. In short, p-tau217 represents a potential non-invasive diagnostic resource. More diverse cohorts are needed to confirm its validity in daily clinical practice.
8 July 2019 in RESPYN Revista Salud Pública y Nutrición
Introducción: En el mundo se pierden cerca de un tercio de todos los alimentos producidos para consumo humano en el mundo, mientras que en Jalisco sólo 68.5% de la población tiene seguridad alimentaria. Objetivo: El objetivo del estudio fue caracterizar a los beneficiarios socio-demográficamente y evaluar seguridad y pobreza alimentaria. Material y método: Se obtuvieron datos del proyecto “Modelo logístico para el aprovechamiento, conservación y manejo de alimentos: plataforma de alimentos (JAL 2016-01-02-279011)” muestreo a conveniencia de familias atendidas por Banco de Guadalajara, Zapotlanejo y Tepatitlán (n=311). Se evaluó el grado de seguridad y pobreza alimentaria, escolaridad, ingreso familiar comparado con la línea de bienestar mínimo, gasto en alimentación; variables cuantitativas en mediana y rango intercuartilar; cualitativas en frecuencia y porcentaje. Resultados: El 97.4% son mujeres, solo 10% de ellas concluyó preparatoria, 75% presentaron sobrepeso u obesidad. Únicamente 7.4% se clasificó como seguridad alimentaria,Guadalajara tuvo el mayor porcentaje con inseguridad alimentaria moderada y severa (29.7% y 4.7%), y Tepatitlán leve (73.5%), 60% del ingreso se destina a alimentación, 78% muestran pobreza alimentaria. Conclusiones: La pobreza alimentaria coexiste con desnutrición y la obesidad, las mujeres son las encargadas del hogar y la alimentación, por lo que debe intervenirse con enfoque de género y la inseguridad alimentaria leve debe considerarse un problema a atender.
Background/Objectives: The 2025 Lancet Diabetes & Endocrinology Commission proposed a framework that distinguishes preclinical from clinical obesity based on confirmed excess adiposity and evidence of obesity-related organ dysfunction. We estimated the prevalence and clinical characteristics of preclinical and clinical obesity in Mexican adults and quantified their discordance with conventional body mass index (BMI) categories. Methods: Cross-sectional analysis of 5014 adults aged ≥20 years (weighted population 77,915,402) from the 2023 Mexican National Health and Nutrition Survey (ENSANUT). Excess adiposity was confirmed by a BMI ≥ 30 kg/m2 plus one altered measure of central adiposity, by two altered measures irrespective of BMI, or by a BMI ≥ 40 kg/m2 alone. Obesity-related dysfunction was ascertained from available cardiovascular, metabolic, and functional indicators. All analyses accounted for the complex sampling design. Results: Preclinical obesity affected 30.9% of adults and clinical obesity 19.6%. Among adults with clinical obesity, 4.9% had a normal BMI and 18.3% were overweight so that 23.2% fell below the conventional 30 kg/m2 threshold. Cardiovascular dysfunction was the most frequent qualifying domain (78.1%), followed by limitations in activities of daily living (27.6%) and metabolic dysfunction (6.7%). Conclusions: BMI alone underestimates obesity-related clinical severity and misses a substantial share of adults with organ dysfunction, supporting the integration of central adiposity measures and assessment of obesity-related dysfunction into routine obesity surveillance.